the weeks ahead, page-2

I can't see how Mark Diamond's call for patience and that planning is in progress can be interpreted as 'nothing will happen for a long time'

I interpreted the opposite in fact.

He was just stating the fact that planning for Phase 2 human trial is being done at the moment. While some posters here may concentrate on the issue of funding and partnering, MD reference to 'planning' is actually referring to the planning of Phase 2, seemingly not concern about the funding of it at all. Don't forget that millions and 7 years of effort has been spent on ATL1103, it is almost a given that it will continue its development.

As for partnering for sight disorder and cancer, it is entirely out of ANP's hands as the pharma will do DD quite independently from what ANP is planning to do on Phase 2 trials. If there is an offer, it will be announced. It could be soon if there is interest.

At the same time Afandin is certainly working concurrently on getting ATL1101 for prostate cancer funded. This year prostate cancer has been the main agenda in a couple of cancer conferences and meetings, oncology R&D is said to be the main focus of big pharms this year. I am sure there will be a lot of interests in using Antisense for cancer research and commercialisation.

Phase II of ATL1102 commenced after 6 months from Phase I result. If Using the same timeframe working backwards, the planning needs to be finalised this month, leaving sufficient time for funding, recruitment of trial subjects, manufacturing of drugs, approval of Phase 2 dosing and trial plan.
If this can be done, Phase 2a trial should commence in June/July, complete by Sept with results in Oct/Nov.
If Phase 2a is successful, it is likely that a deal similar to Mipomersen could be realised. From all the antisense trials do far, Phase 2 safety and toxicology has been getting excellent results. So I am quietly confident that ATL1103 will be successful in Phase 2 trial.

For now till then, those who have the same thought would be accumulating for the big payday this year.

I hope to see a move to 4-5cps when Phase 2 planning and trial is confirmed. 7-9cps when Afandin gets a funding for ATL1101 cancer.
16c before the results of ATL1103 phase 2a. 20-25c if Phase 2 is successful. 40c if a Mipomersen type deal is being offerred.

Just hope that everything will go according to plan.

In the next 3-5 years, can the ex-CSL directors of ANP make another CSL out of ANP?

I sincerely hope so. :)

JIMO. DYOR